Literature DB >> 22017698

Cells, cytokines and inflammatory bowel disease: a clinical perspective.

Ian C Roberts-Thomson1, James Fon, Wendy Uylaki, Adrian G Cummins, Simon Barry.   

Abstract

Ulcerative colitis and Crohn's disease are chronic inflammatory disorders of the GI tract. Although the disorders can usually be distinguished on clinical and pathological criteria, there are similarities in natural history and response to therapy. The purpose of this article is to examine the inflammatory infiltrate in both disorders and the cytokine profiles in intestinal mucosa and peripheral blood. For both disorders, the predominant cells in inflamed mucosa are neutrophils and lymphocytes positive for CD4. There are also increases in the number of B cells, macrophages, dendritic cells, plasma cells, eosinophils and perhaps mast cells. Cytokine levels and cytokine expression are also similar for both disorders, with increases in TNF-α and IFN-γ consistent with a Th1 response. As inflammation occurs in a microbial environment, one possibility is that the nature of the inflammatory response is largely independent of initiating factors. One concept that might be useful is that of initiating cells and cytokines and effector cells and cytokines. Persuasive evidence exists for a defect in phagocytic cells in Crohn's disease, perhaps with the expansion of a subset of activated macrophages. There are also possible links to natural killer cells and changes in the regulation of IL-8 and perhaps IL-22. For ulcerative colitis, the cellular events are less clear, but natural killer T cells may be important as initiating cells, and there is some evidence for upregulation of cytokines involved in Th2 responses, including IL-4 and IL-13. For both disorders, proinflammatory cytokines include TNF-α, IL-12, IL-23, and perhaps IL-17 and IFN-γ. Research challenges include the identification, activation and function of subsets of inflammatory cells, as well as new ways to terminate the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017698     DOI: 10.1586/egh.11.74

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  42 in total

1.  Serum IL-17 and IL-6 increased accompany with TGF-β and IL-13 respectively in ulcerative colitis patients.

Authors:  Jin-Shan Feng; Zheng Yang; Yu-Zhen Zhu; Zhou Liu; Can-Can Guo; Xue-Bao Zheng
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Cardiovascular complications in inflammatory bowel disease.

Authors:  Rudolf Schicho; Gunther Marsche; Martin Storr
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

3.  Sleep and inflammatory bowel disease: exploring the relationship between sleep disturbances and inflammation.

Authors:  Jami A Kinnucan; David T Rubin; Tauseef Ali
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-11

4.  Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients.

Authors:  Lorenzo Bertani; Laura Baglietto; Luca Antonioli; Matteo Fornai; Gherardo Tapete; Eleonora Albano; Linda Ceccarelli; Maria Gloria Mumolo; Carolina Pellegrini; Ersilia Lucenteforte; Nicola de Bortoli; Massimo Bellini; Santino Marchi; Corrado Blandizzi; Francesco Costa
Journal:  Br J Clin Pharmacol       Date:  2020-02-18       Impact factor: 4.335

Review 5.  Laboratory markers in ulcerative colitis: Current insights and future advances.

Authors:  Michele Cioffi; Antonella De Rosa; Rosalba Serao; Ilaria Picone; Maria Teresa Vietri
Journal:  World J Gastrointest Pathophysiol       Date:  2015-02-15

6.  Adiponectin confers protection from acute colitis and restricts a B cell immune response.

Authors:  Stephanie Obeid; Miriam Wankell; Berenice Charrez; Jade Sternberg; Roxane Kreuter; Saeed Esmaili; Mehdi Ramezani-Moghadam; Carol Devine; Scott Read; Prithi Bhathal; Andreas Lopata; Golo Ahlensteil; Liang Qiao; Jacob George; Lionel Hebbard
Journal:  J Biol Chem       Date:  2017-03-03       Impact factor: 5.157

Review 7.  Immune-epithelial crosstalk at the intestinal surface.

Authors:  Nadine Wittkopf; Markus F Neurath; Christoph Becker
Journal:  J Gastroenterol       Date:  2014-01-28       Impact factor: 7.527

8.  STAT1, STAT6 and adenosine 3',5'-cyclic monophosphate (cAMP) signaling drive SOCS3 expression in inactive ulcerative colitis.

Authors:  Yi Li; Jasper Deuring; Maikel P Peppelenbosch; Ernst J Kuipers; Colin de Haar; C Janneke van der Woude
Journal:  Mol Med       Date:  2012-12-20       Impact factor: 6.354

Review 9.  Remote ischemic preconditioning as treatment for non-ischemic gastrointestinal disorders: beyond ischemia-reperfusion injury.

Authors:  Carlos Rodrigo Camara-Lemarroy
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

10.  Interleukin 6 inhibition by triptolide prevents inflammation in a mouse model of ulcerative colitis.

Authors:  Haifeng Zhang; Weichang Chen
Journal:  Exp Ther Med       Date:  2017-07-11       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.